A historic moment: WHO recommends deployment of a malaria vaccine finally developed after a 100-year endeavour. The WHO have advised that the RTS,S/AS01 vaccine, also known as Mosquirix, developed by GlaxoSmithKline (London, England) over the last 30 years in…
Phase III trials for the VLA1553 vaccine against chikungunya virus indicated promising results by inducing protective CHIKV neutralizing antibody titers…
Complete the form below to get your free COVID-19 pathogenesis, prevention and treatment eBook. Receive three free articles from our…
Novel and emerging infectious diseases can be a serious threat to human health and the global economy. To mitigate these…
The ‘inevitable’ domination of novel SARS-CoV-2 variants from Brazil, South Africa and the UK could result in less effective COVID-19…
Up to 5000 immunocompromised people from across the UK are set to be vaccinated as part of the Octave study…
The first national population-level study has shed light on the effect of the first dose of the COVID-19 vaccine. The…
Pfizer and BioNTech’s COVID-19 vaccine has been approved for use by the UK’s regulator, MHRA, making it the first COVID-19…
While the latest set of interim vaccine results from Oxford University and AstraZeneca include an efficacy score of 70%, significantly…
Just 1 week after Pfizer and BioNTech’s early Phase III trial data were released, more good news comes from Moderna’s…
